Previous Article | Next Article ![]()
Infect. Immun., 05 1996, 1659-1665, Vol 64, No. 5
AI Fattom, J Sarwar, A Ortiz and R Naso
The efficacy of capsular polysaccharide (CP)-specific antibodies elicited
by active immunization with vaccines composed of Staphylococcus aureus
types 5 and 8 CP linked to Pseudomonas aeruginosa exoprotein A or with
immune immunoglobulin G (I-IgG) obtained from vaccinated plasma donors was
tested in lethal and sublethal bacterial mouse challenge models. A dose of
2 x 10(5) CFU of S. aureus type 5 CP per mouse administered
intraperitoneally (i.p.) with 5% hog mucin was found to cause 80 to 100%
mortality in BALB/c mice within 2 to 5 days. Mice passively immunized i.p.
24 h earlier or subcutaneously 48 h earlier with 0.5 ml of I-IgG showed
significantly higher average survival rates than animals receiving standard
IgG or saline (P < 0.01) following the bacterial challenge. Animals
actively immunized with the monovalent type 5 CP-P. aeruginosa exoprotein A
conjugate showed a survival rate of 73% compared with 13% in
phosphate-buffered saline- immunized animals. The prechallenge geometric
mean titer of type 5 CP antibodies in animals that died was significantly
(P < 0.05) lower than that of animals which survived the challenge (95.7
versus 223.6 micrograms/ml, respectively). The IgG was further evaluated in
mice challenged i.p. with a sublethal dose of 5 x 10(4) CFU per mouse.
Serial blood counts were performed on surviving animals at 6, 12, 24, and
48 h. Surviving animals were sacrificed at 72 h, and bacterial counts were
performed on their kidneys, livers, and peritoneal lavage fluids. Animals
receiving I-IgG had lower bacterial counts in blood samples and lower
bacterial densities in kidneys, livers, and peritoneal lavage samples than
mice immunized with standard IgG (P < 0.05). These data suggest that S.
aureus type 5 CP antibodies induced by active immunization or administered
by passive immunization confer protection against S. aureus infections.
Copyright © 1996, American Society for Microbiology
A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP- specific antibodies protect mice against bacterial challenge
W.W. Karakawa Microbial Pathogenesis Laboratory, NABI, Rockville, Maryland 20852, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|